Rznomics Inc. (KOSDAQ:476830)

South Korea flag South Korea · Delayed Price · Currency is KRW
186,800
-10,000 (-5.08%)
At close: Apr 28, 2026
107.56%
Market Cap 2.60T
Revenue n/a
Net Income n/a
Shares Out 13.93M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 322,866
Average Volume 463,586
Open 192,900
Previous Close 196,800
Day's Range 186,500 - 198,700
52-Week Range 90,000 - 245,250
Beta n/a
RSI 47.81
Earnings Date n/a

About Rznomics

Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476830
Full Company Profile

News

There is no news available yet.